# US 2016/0257960 A9 · Mcpip protection against osteoclast production

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257960 A9
- Document ID: US20160257960A9
- Status: Published application
- Kind: A9
- Application number: 14/194,254
- Filed: 2014-02-28
- Published: 2016-09-08
- Earliest claimed: 2005-12-20
- Assignees: University of Central Florida Research Foundation, Inc.
- Inventors: Pappachan Kolattukudy
- Web page: https://patentgrep.com/patent/US20160257960A9

## CPC

- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 16/18: against material from animals or humans
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed herein are methods of treating a patient at risk of developing an inflammatory joint disease. In exemplary embodiments, the method involves inhibiting MCPIP levels in a patient in need, wherein said patient in need is exhibiting pre-arthritic or pre-osteoporotic symptoms.

## Claims

### Claim 1

A method of treating a condition in a patient in need, the method comprising administering to the patient a therapeutically effective amount of a composition that inhibits the expression or action of MCPIP, wherein said condition comprises abnormal osteoclast-induced bone resorption.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient in need is exhibiting pre-arthritic symptoms.

### Claim 3 (depends on 1)

The method of claim 1, wherein the patient in need is exhibiting pre-osteoporotic symptoms.

### Claim 4 (depends on 1)

The method of claim 1 wherein the composition comprises siRNA specific for MCPIP.

### Claim 5 (depends on 1)

The method of claim 1 wherein the composition comprises an antisense nucleotide specific for MCPIP.

### Claim 6 (depends on 1)

The method of claim 1 wherein the composition comprises shRNA.

### Claim 7 (depends on 1)

The method of claim 1 wherein the composition comprises an antibody specific to MCPIP.

### Claim 8 (depends on 1)

The method of claim 1, wherein the composition is administered to the patient via intrabuccal, oral, rectal, pulmonary, ocular, or transdermal administration.

### Claim 9 (depends on 1)

The method of claim 1, wherein the condition comprises an osteoporosis-related condition.

### Claim 10 (depends on 1)

The method of claim 1, wherein the condition comprises Rheumatoid Arthritis.

### Claim 11 (depends on 1)

The method of claim 1, wherein inhibiting MCPIP levels comprises directly administering the composition to the patient in need.

### Claim 12 (depends on 1)

The method of claim 1, wherein administering the composition comprises administering a composition comprising a therapeutically effective amount of the composition that inhibits the expression or action of MCPIP and a pharmaceutically acceptable excipient.

### Claim 13

A method of inhibiting osteoclast production in a patient in need, comprising:
administering a therapeutically effective amount of a composition that inhibits the expression or action of MCPIP in the patient.

### Claim 14 (depends on 13)

The method of claim 13, wherein the patient in need is exhibiting symptoms of rheumatoid arthritis, osteoarthritis, and/or osteoporosis.

### Claim 15 (depends on 13)

The method of claim 13, wherein administering a therapeutically effective amount of a composition includes a composition comprising: a composition that inhibits the expression or action of MCPIP, and a pharmaceutically acceptable excipient.

### Claim 16 (depends on 13)

The method of claim 13, wherein the composition includes an MCPIP siRNA, an shRNA, an antibody specific to MCPIP, and/or an antisense nucleotide specific for MCPIP.

### Claim 17 (depends on 1)

The method of claim 1, wherein the condition is an inflammatory joint disease.

### Claim 18

A method of treating an inflammatory disease in a patient in need thereof, said method comprising:
procuring human bone marrow mononuclear cells (BMCs) from said patient to obtain procured BMC's;
treating said procured BMC's, ex vivo, by blocking expression of MCPIP in said cells to obtain treated BMC's;
administering said treated BMC's to said patient.

### Claim 19 (depends on 18)

The method of claim 18, wherein said treating comprises subjecting said procured BMC's to an antisense nucleotide specific to an mRNA sequence encoding MCPIP.

### Claim 20 (depends on 18)

The method of claim 18, wherein said treating comprises subjecting said procured BMC's to an antibody specific to MCPIP.

### Claim 21 (depends on 18)

The method of claim 18, wherein said treating comprises subjecting said procured BMC's to siRNA specific to MCPIP.

### Claim 22 (depends on 18)

The method of claim 18, wherein said inflammatory disease comprises osteoporosis, or arthritis.
